The Le Méridien vaccine (06660) was announced. The group submitted Haemophilus influenzae type b (H...
Zhitong Finance App News, Le Meridien Vaccine (06660) announced that the group submitted a pre-clinical trial application for the Haemophilus influenzae type b (Hib) conjugate vaccine on March 27, 2024, and submitted a pre-clinical trial application for adsorbed tetanus vaccine on February 9, 2024. The development of the above two vaccines is in line with the company's product development strategy layout. It is an important step in achieving the company's development of multi-linked multi-price products, and will further improve the company's product hierarchy.
According to reports, invasive diseases caused by Hib can affect many organs. Common invasive diseases include meningitis, pneumonia, epischemia, arthritis, and cellulitis. The rare types of diseases include osteomyelitis, pericarditis media, and acute bronchitis.
Furthermore, the Group is actively promoting the development of an adsorbed acell-free Haemophilus influenzae type b (DTP-Hib) combination vaccine (hereinafter referred to as “multiple vaccine”). It is expected that applications for clinical trials of the multiple vaccine and its components will be submitted one after another starting in 2024. The polyvaccine can be used to prevent invasive infections caused by pertussis, diphtheria, tetanus, and Haemophilus influenzae type b. It has the advantages of reducing the number of vaccinations for infants and young children and enhancing the vaccination compliance of parents and infants. Polyvaccine is a development trend in the industry. It enhances the company's core competitiveness, strengthens the company's market position, and provides strong support for the company's continued steady development.